登录新浪财经APP 搜索【信披】查看更多考评等级 来源：九州商业观察 12月17日，金花企业（集团）股份有限公司（股票简称：金花股份（维权），代码：600080）一纸公告 揭开了资本市场信息披露违规的典型案例。公司董事长邢雅江因隐瞒2024年4月至7月期间被公安机关取 保候审的关键事实，未及时履行信息披露义务，最终收到陕西证监局的行政处罚决定书——被给予警告 并处以350万元罚款，这一金额远超其2024年112.03万元的税前年薪，成为监管层严打信披违规的又一 重磅案例。 回溯事件始末，2024年4月23日，邢雅江因他人涉嫌私自刻制无关公司印章案被牵连，西安市公安局鄠 邑分局对其采取取保候审措施。同年7月26日，因指证证据发生变化，现有证据无法证实其涉案嫌疑， 公安机关依法解除取保候审。但作为上市公司董事长，邢雅江未在第一时间将这一影响投资者决策的重 大事项报告公司并对外披露，直至2024年8月24日才通过公司公告公开相关信息，违规延迟披露时长超 四个月。 值得关注的是，在监管调查及听证过程中，邢雅江及其代理人提出两项申辩理由：一是声称"客观上无 法确认自身法律状态的变化"，不存在主观过错；二是认为处罚过重， ...

Core Viewpoint - Jinhua Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, attributed to increased R&D expenses and a lack of investment gains from the previous year [1] Financial Performance - For the first half of 2025, Jinhua Co. achieved operating revenue of 241 million yuan, a year-on-year decrease of 1.9% [1] - The net profit attributable to shareholders was 6.195 million yuan, down 34.53% year-on-year [1] - R&D expenses saw a significant increase of 83.2% during the reporting period [1] - The net cash flow from operating activities was -80.93 million yuan [1] Stock Performance - As of August 21, 2025, Jinhua Co. shares closed at 8.08 yuan, up 0.62% from the previous trading day [1] - The trading volume for the day was 65,858 hands, with a transaction amount of 53 million yuan and a fluctuation of 1.74% [1] - On August 21, 2025, the net outflow of main funds was 2.3434 million yuan, accounting for 0.08% of the circulating market value [1] - Over the past five days, the net inflow of main funds was 6.3297 million yuan, representing 0.21% of the circulating market value [1] Product Line - Jinhua Co. is engaged in the research, production, and sales of pharmaceuticals, with a product line that includes chemical drugs, traditional Chinese medicine, raw materials, and health products [1] - The company's leading product, Jintian Ge capsules, is a national Class I new drug and has become a first-line medication in orthopedic clinical practice [1] - The company also offers a range of pediatric medications, including children's cough syrup [1]

Core Viewpoint - The chairman of Jinhua Co., Xing Yajiang, is under investigation for stock disclosure violations, leading to a significant fine of 3.5 million yuan, highlighting a series of governance and financial issues within the company [1][2]. Group 1: Chairman's Involvement and Regulatory Actions - Xing Yajiang was placed under criminal detention in April 2024 but reported to the company only four months later, resulting in severe disclosure delays [2]. - The Shaanxi Securities Regulatory Bureau criticized Xing for failing to fulfill his duties, issuing a personal fine of 3.5 million yuan, marking the second major penalty since the investigation began [2]. Group 2: Financial Irregularities and Mismanagement - Jinhua Co. transferred 52 million yuan to a company controlled by the chairman through prepayments, indicating typical related-party fund occupation [3]. - The company misappropriated fundraising for stock trading, ultimately needing to borrow 30 million yuan from individuals to cover losses [3]. - The 2023 third-quarter report concealed a loss of 4.99 million yuan, falsely reporting a profit of 3.39 million yuan, reflecting a 247% discrepancy [3]. Group 3: Audit Concerns and Project Delays - The auditing firm issued a non-standard opinion for the 2024 report, highlighting three major risks: questionable prepayments of 30.03 million yuan, uncertainty regarding the pledge of 39.5 million yuan in deposits, and delays in a 600 million yuan new factory project initiated in 2018 [4]. - These irregular transactions coincided with the period when the Xing family gained full control of the company [4]. Group 4: Product Dependency and Revenue Challenges - The company's primary product, Jintian Ge Capsule, accounts for 80% of revenue but faces innovation challenges, with R&D investment consistently below 3% of revenue from 2018 to 2024 [5]. - Revenue has fluctuated between 530 million and 580 million yuan over the past four years, with net profits showing a volatile pattern of losses and gains [5]. Group 5: Governance Crisis and Future Risks - The governance crisis at Jinhua Co. extends beyond individual cases, with the controlling family under judicial investigation and continuous warnings from auditing firms [6]. - The company is at a crossroads between potential delisting risks and the need for value reassessment, with systemic control risks lurking behind financial data [6].

Core Viewpoint - The chairman of Jinhua Enterprises (Group) Co., Ltd., Xing Yajiang, has been penalized by the China Securities Regulatory Commission (CSRC) for information disclosure violations, receiving a warning and a fine of 3.5 million yuan, with further investigations ongoing [1][2]. Group 1: Regulatory Actions - Xing Yajiang has been placed under criminal detention from April to July 2024 for suspected crimes, failing to report this to the company in a timely manner [2]. - The CSRC has initiated a case against Xing Yajiang for violations related to the disclosure of shareholding changes [2][10]. - This is not the first time Xing Yajiang has faced regulatory scrutiny; he was previously notified of a case by the CSRC in December 2023 for similar violations [3]. Group 2: Company Performance - Jinhua Enterprises reported revenues of 5.85 billion yuan in 2024, a year-on-year increase of 3.55%, with a net profit of 75 million yuan, marking a significant turnaround from previous losses [5]. - The company's profitability in 2024 was primarily driven by the disposal of its wholly-owned subsidiary, Jinhua International Hotel Co., Ltd., which generated an investment income of 34.33 million yuan [5]. - However, in the first quarter of 2024, the company experienced a revenue decline of 7.31% year-on-year, with a net profit drop of 94.93% [6]. Group 3: Disclosure Issues - Jinhua Enterprises has faced multiple regulatory warnings in 2024 due to inaccurate earnings forecasts and failure to disclose the chairman's criminal detention in a timely manner [7][9]. - The company was criticized by the Shanghai Stock Exchange for discrepancies between its earnings forecast and actual results, with variances of nearly 105% for net profit [8]. - The company was required to correct its earnings forecast and disclose the chairman's situation only after regulatory intervention [9].